Xbrane And Biogen End Deal For Cimzia Biosimilar
Terminating Alliance On Certolizumab Pegol Will Set Back Xbrane’s Break-Even Goals
Biogen has decided to terminate an alliance with Xbrane Biopharma linked to the firm’s proposed biosimilar to Cimzia (certolizumab pegol). The move represents the latest setback for Xbrane, with the firm acknowledging that losing Biogen as a partner will impact its financial goals over the next year.
